An earlier study by Oshima suggested that mutations in SMAD4 were significantly associated with tumor size, lymphatic infiltration, and lymph node metastasis, whereas CDKN2A mutations were associated with lymphatic infiltration and extensive postoperative metastasis. This evidence concerns the gene SMAD4 and neoplasm.